Treatment-resistant depression (TRD), characterized by frequent relapses, diminished quality of life, and increased mortality, affects approximately 50% of patients with depression and often necessitates poly-pharmacological treatments [
1]. Intermittent theta burst stimulation (iTBS), a newer form of repetitive transcranial magnetic stimulation was developed in 2005, has received the U.S. Food and Drug Administration (FDA) approval as an augmentation strategy for depression in 2019 [
2,
3]. Consequently, researchers are particularly engaged in exploring the efficacy and optimal techniques of accelerated, intensive or prolonged iTBS (piTBS) protocols, which are proposed to provide options in more severe forms of TRD. While the Stanford Neuromodulation Therapy (SNT) [
4] protocol is a prominent FDA-cleared example, various studies have documented piTBS5 which consists of once a daily session for roughly 4 to 6 weeks, and accelerated protocols (accelerated iTBS [aiTBS]) involving multiple daily sessions within relatively shorter time period (few days to 2 weeks) [
6-
8]. Despite iTBS’s FDA approval for TRD, its clinical applicability is constrained by its 6-week duration [
3], prompting investigations into accelerating TBS delivery. These investigations focus on optimizing minimal treatment duration, total pulse number, and magnetic intensity to enhance efficacy and treatment adherence. A significant challenge in this area is the absence of standardized stimulation parameters across various research groups, contributing to this shortfall. Addressing the standardization issue has recently become a prominent topic among study groups using aiTBS [
9].
This correspondence shares our findings on a less time-, labour-intensive, yet feasible, aiTBS protocol: three daily sessions delivered over 10 days. Beyond, we aim to advocate for a consensus on aiTBS protocols, which will facilitate comparative studies and the generation of meta-analytical evidence from various research and clinical trials.
Our small cohort consists of four consecutive outpatients who were referred from the outpatient clinic of Hacettepe University Department of Psychiatry with the diagnosis of TRD in September and October 2023. At baseline, the mean symptom scores (with standard deviations) for the four cases were as follows: 28.5 (7.54) on the Montgomery-Åsberg Depression Rating Scale (MADRS), 19.5 (5.06) on the Hamilton Depression Rating Scale-17 (HDRS-17), and 9.75 (0.50) on the Maudsley Staging Method (MSM). The cases are summarized in
Table 1, and each case is elaborated in the
Supplementary Material. We implemented an aiTBS protocol with sessions spaced at least 40 minutes apart, each delivering 1,800 pulses (triplet 50 Hz bursts, repeated at 5 Hz for 2 seconds with 8 seconds intertrain intervals) at 90% resting motor threshold (rMT) and conducted over 2 weeks, with three sessions per day and 5 days per week (total of 54,000 pulses). We targeted the left dorsolateral prefrontal cortex using the F3-Beam method with a Neuro-MS/D device and figure-of-8 coil (Neurosoft Neuro-MS/D). Patients maintained their pharmacological treatments throughout the aiTBS process. Treatment outcomes are presented in
Table 1 and
Supplementary Table 1. Regarding side effects, case 3 reported headaches during treatment sessions, resolving with paracetamol. All patients responded (≥50% decrease in the HDRS-17) to the 2-week treatment, although one case showed relapse in the first month post-treatment. Seventy-five percent of patients were in full remission (HDRS-17 ≤7 at the end of the first 4-week post-treatment). The patient who experienced a relapse of depression presented with the most severe baseline depressive symptoms, as indicated by a MADRS score of 39 and a HDRS-17 score of 26. Additionally, this patient had a comorbid diagnosis of attention-deficit/hyperactivity disorder, which may have contributed to the relapse.
We presented previous evidence supporting our protocol and compared our protocol with previous ones in
Table 2. Although our protocol was never investigated in a randomized controlled trial (RCT) design, this protocol was similar to previous report by Richard et al. [
10], except for intensity being lower (120% vs. 90% rMT) and intersession interval being higher (50 minutes vs. 40 minutes). However, the aforementioned report indicated that the remission rates were suboptimal. We conducted aiTBS at sub-threshold intensity since it was indicated by previous studies that sub-threshold is not inferior to supra-threshold stimulation [
6]. Additionaly when RCT are evaluated in terms of intensity, 90% rMT [
4] achieved the highest remission rate (
Table 2) [
4,
6,
7,
11]. We delivered sessions spaced 40 minutes apart because sessions with intersession intervals of 30 minutes or less do not produce a cumulative effect on synaptic strengthening [
12,
13].
This protocol’s advantages include fewer daily sessions compared to other studies [
2], lower stimulation intensity reducing seizure risks, and a shorter overall treatment period. We observed significant improvements using sub-threshold (90% rMT) stimulation intensity, aligning with studies suggesting that sub-threshold intensities can be as effective as suprathreshold intensities in modulating cortical properties [
14]. Notably, this supports the notion that lower intensities may maintain treatment efficacy, also possibly reducing the risk of seizures [
15], especially in the prefrontal cortex.
The current landscape of aiTBS research lacks uniformity in protocol design, particularly regarding the total number of pulses, stimulation intensity, and daily number of iTBS sessions [
2]. One of the most popular among them, the SNT, involves 10 daily sessions over 5 days, showing a 64.3% response rate in highly treatment-resistant (the average of score on MSM: 9±2) cases [
4]. However, such a protocol, involving up to 10 sessions a day with hourly intervals, presents practical challenges as it necessitates engaging a patient in treatment for an entire day, often surpassing standard working hours. In conclusion, we presented a case series where we used an effective, safe, and feasible aiTBS protocol for TRD, consisting of 5 days per week of three daily sessions over 2 weeks. We strongly advocate for the establishment of a consensus and protocol guidelines in aiTBS research, focusing on optimizing iTBS parameters for greater efficacy and accessibility in treating depression.
We obtained written informed consent from all of four patients for the case presentation.
Notes
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Conflicts of Interest
The authors have no potential conflicts of interest to disclose.
Author Contributions
Conceptualization: all authors. Data curation: all authors. Formal analysis: Doğukan Koçyiğit, Şeref Can Gürel. Methodology: Şeref Can Gürel. Supervision: Şeref Can Gürel. Validation: Şeref Can Gürel. Writing—original draft: Doğukan Koçyiğit, İrem Kübra Nur Canpolat. Writing—review & editing: all authors.
Funding Statement
None
Acknowledgments
We thank to medical secretary Tülay Karayılan and nurse Selda Bayri at the psychiatric interventions unit for their contributions.
Table 1.
Definition of the cases and aiTBS outcomes
|
Case 1 |
Case 2 |
Case 3 |
Case 4*
|
|
Sociodemographic aspects |
|
|
|
|
|
Sex |
Female |
Male |
Female |
Male |
|
Diagnosis |
MDD |
MDD |
MDD |
MDD |
|
Age (yr) |
58 |
24 |
28 |
29 |
|
Education (yr) |
8 |
13 |
17 |
14 |
|
Unemployed/functionally disabled |
Yes |
Yes |
Yes |
Yes |
|
Cilinical aspects |
|
|
|
|
|
Age at MDD onset (yr) |
33 |
19 |
17 |
16 |
|
Length of illness (yr) |
25 |
5 |
11 |
13 |
|
Number of depressive episodes |
7 |
3 |
4 |
5 |
|
History of depressive episode with psychotic features |
No |
Yes |
No |
No |
|
Maudsley Staging Method |
10 |
9 |
10 |
10 |
|
Duration of current episode (mon) |
24 |
12 |
18 |
14 |
|
Presence of psychotic features in current episode |
No |
No |
No |
No |
|
Chief complaints |
Insomnia, weight loss, anhedonia, depressed mood |
Anhenodonia, thoughts of death, not be able to concentrate |
Anhenodonia, sleep-maintenance insomnia, loss of energy |
Psychomotor retardation, difficulty concentrating, depressed mood, hypersomnia |
|
Psychiatric comorbidities |
No |
No |
OCD |
ADHD |
|
Family history of mood disorder |
MDD |
No |
BAP, MDD |
No |
|
Psychiatric hospitalizations |
0 |
0 |
0 |
1 |
|
aiTBS outcomes |
|
|
|
|
|
Pre-aiTBS (MADRS, HAM-D) |
23, 15 |
23, 21 |
29, 16 |
39, 26 |
|
Day 7 (MADRS, HAM-D) |
20, 13 |
10, 11 |
13, 10 |
35, 16 |
|
Day 14 (MADRS, HAM-D) |
17, 10 |
5, 3 |
9, 9 |
18, 13 |
|
Month 1 (MADRS, HAM-D) |
8, 6 |
6, 3 |
9, 6 |
35, 20 |
Table 2.
aiTBS protocols investigated in randomized controlled trials, and the presented protocol
|
Duprat et al., [11] 2016 |
Chen et al., [6] 2021*
|
Wilkening et al., [7] 2022 |
Cole et al., [4] 2022 |
Presented protocol |
|
Session plan |
|
|
|
|
|
|
Number of sessions per a day |
5 |
2 or 3 |
2 |
10 |
3 |
|
Number of days per a week |
4 |
4 |
5 |
5 |
5 |
|
Number of weeks |
1 |
2 |
2 |
1 |
2 |
|
Total number of sessions |
20 |
20 |
20 |
50 |
30 |
|
Pause minutes between sessions |
15 |
15 |
20-30 |
50 |
40 |
|
Stimulation aspects |
|
|
|
|
|
|
Stimuli per session |
1,620 |
1,200 |
1,800 |
1,800 |
1,800 |
|
Total stimuli |
32,400 |
24,000 |
36,000 |
90,000 |
54,000 |
|
Triplet burst |
54 |
50 |
50 |
50 |
50 |
|
Train duration (sec) |
2 |
2 |
2 |
2 |
2 |
|
Intertrain interval (sec) |
8 |
8 |
8 |
8 |
8 |
|
Intensity |
110% of rMT |
80%-120% of rMT |
110% of rMT |
90% of rMT |
90% of rMT |
|
Coil placement |
The Brainsight neuronavigation system, Broadman 9/46 |
F3-Beam method, Bilateral, F3-F4 |
F3-Beam method, unilateral, F3 |
Localite neuronavigation system |
F3-Beam method, unilateral, F3 |
|
Clinical utilization |
|
|
|
|
|
|
Patients’ diagnosis |
TRD |
TRD |
TRD |
TRD |
TRD |
|
Number of patients |
50 |
180 |
40†
|
29†
|
4 |
|
Severity of resistance of depression |
N/A |
N/A |
N/A |
MSM=9±2 |
MSM=9.75±0.50 |
|
Response and remission rate |
38%-30% |
40.5%-20% |
39%-39% |
64.3%-42.9% |
75%-75% |
REFERENCES
2. Conroy SK, Holtzheimer PE. Neuromodulation strategies for the treatment of depression. Am J Psychiatry 2021;178:1082-1088.
3. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREED): a randomised non-inferiority trial. Lancet 2018;391:1683-1692.
4. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry 2022;179:132-141.
5. Li CT, Cheng CM, Chen MH, Juan CH, Tu PC, Bai YM, et al. Antidepressant efficacy of prolonged intermittent theta burst stimulation monotherapy for recurrent depression and comparison of methods for coil positioning: a randomized, double-blind, sham-controlled study. Biol Psychiatry 2020;87:443-450.
6. Chen L, Thomas EHX, Kaewpijit P, Miljevic A, Hughes R, Hahn L, et al. Accelerated theta burst stimulation for the treatment of depression: a randomised controlled trial. Brain Stimul 2021;14:1095-1105.
8. Sivlim S, Özden HC, Yağcioğlu AEA, Gürel ŞC. Remissıon and follow-up in bipolar depressıon with accelerated intermıttent theta burst stımulatıon protocol. Turk Psikiyatri Derg 2025;36:30
9. Batail JV, Feyder MT, Bentzley BS, Williams NR. An avenue for optimization of theta burst stimulation protocols? Comments on the FOUR-D randomized noninferiority clinical trial. Am J Psychiatry 2024;181:68-70.
10. Richard M, Noiseux C, Desbeaumes Jodoin V, Blumberger DM, Sheen J, Mansouri F, et al. Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. Psychiatry Res 2022;315:114709
11. Duprat R, Desmyter S, Rudi de R, van Heeringen K, Van den Abbeele D, Tandt H, et al. Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: a fast road to remission? J Affect Disord 2016;200:6-14.